TY - JOUR
T1 - Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder
T2 - Secondary Analysis of a Randomized Placebo-Controlled Trial
AU - van Andel, Dorinde M.
AU - Sprengers, Jan J.
AU - Königs, Marsh
AU - de Jonge, Maretha V.
AU - Bruining, Hilgo
N1 - Publisher Copyright:
© The Author(s) 2022.
PY - 2024/3
Y1 - 2024/3
N2 - We present the secondary-analysis of neurocognitive tests in the ‘Bumetanide in Autism Medication and Biomarker’ (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment (≤ 1 mg twice-daily) in unmedicated children 7–15 years with ASD. Children with IQ ≥ 70 were analyzed for baseline deficits and treatment-effects on the intention-to-treat-population with generalized-linear-models, principal component analysis and network analysis. Ninety-two children were allocated to treatment and 83 eligible for analyses. Heterogeneous neurocognitive impairments were found that were unaffected by bumetanide treatment. Network analysis showed higher modularity after treatment (mean difference:-0.165, 95%CI:-0.317 to − 0.013,p =.034) and changes in the relative importance of response inhibition in the neurocognitive network (mean difference:-0.037, 95%CI:-0.073 to − 0.001,p =.042). This study offers perspectives to include neurocognitive tests in ASD trials.
AB - We present the secondary-analysis of neurocognitive tests in the ‘Bumetanide in Autism Medication and Biomarker’ (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment (≤ 1 mg twice-daily) in unmedicated children 7–15 years with ASD. Children with IQ ≥ 70 were analyzed for baseline deficits and treatment-effects on the intention-to-treat-population with generalized-linear-models, principal component analysis and network analysis. Ninety-two children were allocated to treatment and 83 eligible for analyses. Heterogeneous neurocognitive impairments were found that were unaffected by bumetanide treatment. Network analysis showed higher modularity after treatment (mean difference:-0.165, 95%CI:-0.317 to − 0.013,p =.034) and changes in the relative importance of response inhibition in the neurocognitive network (mean difference:-0.037, 95%CI:-0.073 to − 0.001,p =.042). This study offers perspectives to include neurocognitive tests in ASD trials.
KW - ASD
KW - Bumetanide
KW - Child
KW - Cognition
KW - Neurocognitive functioning
KW - RCT
UR - http://www.scopus.com/inward/record.url?scp=85145889834&partnerID=8YFLogxK
U2 - 10.1007/s10803-022-05841-3
DO - 10.1007/s10803-022-05841-3
M3 - Article
C2 - 36626004
AN - SCOPUS:85145889834
SN - 0162-3257
VL - 54
SP - 894
EP - 904
JO - Journal of Autism and Developmental Disorders
JF - Journal of Autism and Developmental Disorders
IS - 3
ER -